Exhaled nitric oxide levels to guide treatment for children with asthma.
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Description of the condition
Asthma is one of the most common chronic diseases in children. Acute flare-ups (exacerbations) are common in children with asthma and some require more intensive treatment in hospital. Hospitalisations for asthma account for 12 to 21% (Anderson 2007; Akinbami 2009 ) of hospitalisations worldwide . Thus prevention of exacerbations, particularly severe exacerbations, is one goal of good asthma management. The second component in asthma management is monitoring of asthma control (by subjective and objective measures) (BTS/SIGN 2014; GINA 2014; National Asthma Council 2014) . Subjective measures usually involve a series of questions used for clinical assessment, diary cards and quality of life (QoL) questionnaires. Traditional objective methods include peak flow, spirometry and degree of airway hyperresponsiveness (Zacharasiewicz 2005) . Newer and arguably more sensitive methods include measurement of airway inflammation such as airway cellularity in induced sputum or fractional exhaled nitric oxide (FeNO) .
Airway inflammation associated with asthma can be eosinophilic or neutrophilic (Douwes 2002) . Arguably, asthma management is best tailored in accordance to the type of airway inflammation, as corticosteroids is more beneficial in eosinophilic inflammation (Wardlaw 2000) ; inhaled corticosteroids (ICS) reduce exacerbations and improves symptoms and asthma control (Wardlaw 2000) . There are several ways to quantify airway eosinophilic inflammation, such as determining the percentage of eosinophils in the sputum and FeNO. FeNO correlates with other markers of asthma e.g. eosinophilia in induced sputum (Jatakanon 1998) and bronchial reactivity in non-steroid treated subjects (Dupont 1998) .
Description of the intervention
The principle of asthma management is based on a stepup or step-down regimen of asthma medications to reduce airway inflammation, control symptoms and reduce exacerbations. Thus tailoring of asthma medications in accordance to airway eosinophilic levels may improve asthma control and/or reduce exacerbations. Obtaining induced sputum samples and sputum analysis is labour intensive and not widely available in most routine clinical settings. Hypertonic saline, used to induce sputum may also temporarily increase asthma symptoms (such as wheeze, cough and chest tightness) and sputum is not always successfully obtained in young children. Thus, measures of FeNO confer some advantage over measurements of sputum eosinophils. However, assessment of FeNO levels do not provide any data on noneosinophilic inflammation and the equipment required to measure FeNO is relatively expensive.
FeNO levels can be measured using commercially available analysers. These analysers vary in several ways that include methods of measurements (on-line or o -line), complexity, their set up, calibration procedures, sampling tube design, measuring chamber and the way expiratory flow is controlled (Muller 2005) . The stationary analysers measure FeNO by chemoluminescence whilst the portable FeNO analysers measure FeNO using electrochemistry.
How the intervention might work
As FeNO is reflective of airway eosinophilia in some circumstances, FeNO can be considered as a biomarker. For asthma, FeNO levels can be potentially used in children with asthma to:
• monitor airway eosinophilia • verify the adherence to ICS, and • predict upcoming asthma exacerbations.
Reduction of airway inflammation improves symptoms and asthma control (Wardlaw 2000) . Hence, the use of FeNO levels to tailor asthma medications in children with asthma may improve asthma control and/or reduce exacerbations.
Why it is important to do this review
A previous Cochrane Review analysed adults and children together (Petsky 2009 ). Given the clinical heterogeneity between children and adults, rather than update that review, we plan to undertake separate reviews for children and adults, this protocol focuses on children and there will be a similar systematic review that includes only adult participants.
A systematic review evaluating the e icacy of tailoring asthma interventions based on FeNO levels will be useful to guide clinical practice in children with asthma. Using FeNO routinely in clinical practice adds to the burden of asthma care and resource utilisation. On the other hand, routine use of FeNO to guide use of asthma medications may improve asthma control and reduce exacerbations and hospitalisations related to asthma.
O B J E C T I V E S
To evaluate the e icacy of tailoring asthma medications based on exhaled nitric oxide (FeNO) for asthma related outcomes in children. We will compare this with not using FeNO i.e. management based on clinical symptoms (with or without spirometry/peak flow) and/or asthma guidelines.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) comparing adjustment of asthma medications based on exhaled nitric oxide (FeNO) levels in comparison to those not using FeNO i.e. management based on clinical symptoms (with or without spirometry/peak flow) and/or current asthma guidelines.
Types of participants
We will include children/adolescents with a diagnosis of asthma according to a guideline defined criteria.
We will exclude participants with the following co-morbidities/ characteristics: eosinophilic bronchitis, asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive pulmonary disease (COPD), or diagnostic categories such as 'cough variant asthma' and 'wheezy bronchitis'.
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Types of interventions
We will include RCTs comparing adjustment of asthma medications based on FeNO levels versus control groups where FeNO is not used to adjust asthma medications. Control group interventions may includes use of clinical symptoms (with or without spirometry/ peak flow) to guide adjustment of asthma medications. Trials that included the use of other interventions will be included if all participants had equal access to such interventions. We will include trials of at least 12 weeks duration.
Types of outcome measures
Primary outcomes
Asthma exacerbations during follow-up. Defined as: Reporting one of more of the outcomes listed here in the trial is not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Trials Search Co-ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We will search all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials portal (www.who.int/ ictrp/en/). We will search all databases from their inception to the present, and we will impose no restriction on language of publication. We will include studies reported as full-text, those published as abstract only, and unpublished data.
Searching other resources
We will check reference lists of all primary studies and review articles for additional references. We will search relevant manufacturers' websites for trial information.
We will search for errata or retractions from included studies published in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two authors (HP, KK) will independently screen titles and abstracts for inclusion of all the potential studies we identify as a result of the search and code them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We will retrieve the full-text study reports/publication and two review authors (HP, KK) will independently screen the full-text and identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third person (AC). We will identify and exclude duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We will record the selection process in su icient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table.
Data extraction and management
We will use a data collection form for study characteristics and outcome data which has been piloted on at least one study in the review. One review author (HP) will extract study characteristics from included studies. A second review author (KK) will spot-check study characteristics for accuracy against the trial report. We will extract the following study characteristics.
1. Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study. 2. Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria.
Interventions:
intervention, comparison, concomitant medications, and excluded medications. 4. Outcomes: primary and secondary outcomes specified and collected, and time points reported. 5. Notes: funding for trial, and notable conflicts of interest of trial authors.
Two review authors (HP, KK) will independently extract outcome data from included studies from current search. We will note in the 'Characteristics of included studies' table if outcome data was not reported in a usable way. We will resolve disagreements by consensus or by involving a third person (AC). One review author (HP) will transfer data into the Review Manager (RevMan) file. We will double-check that data is entered correctly by comparing the data presented in the systematic review with the study reports.
Assessment of risk of bias in included studies
Two review authors (HP, KK) will independently assess risk of bias for each new study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011 ). We will resolve any disagreements by discussion or by involving another author (AC). We will assess the risk of bias according to the following domains.
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We will grade each potential source of bias as high, low or unclear and provide a quote from the study report together with a justification for our judgment in the 'Risk of bias' table.
We will summarise the risk of bias judgements across di erent studies for each of the domains listed. We will consider blinding separately for di erent key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very di erent than for a patient reported pain scale). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table.
When considering treatment e ects, we will take into account the risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic review
We will conduct the review according to this published protocol and report any deviations form it in the 'Di erences between protocol and review' section of the systematic review.
Measures of treatment e ect
We will analyse dichotomous data as odds ratios and continuous data as mean di erence (MD) or standardised mean di erence (SMD). We will enter data presented as a scale with a consistent direction of e ect.
We will undertake meta-analyses only where this is meaningful i.e. if the treatments, participants and the underlying clinical question are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and interquartile ranges.
Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta-analysis, we will halve the control group to avoid double-counting.
Unit of analysis issues
For dichotomous data, we will report the proportion of participants contributing to each outcome in comparison with the total number randomised. For rate ratios of common events whereby one participant may have more than one event, generic inverse variance analysis (GIV), will be used. The rate ratios will be taken from the published papers and the standard errors calculated from confidence intervals or P values published in the papers. For crossover studies, mean treatment di erences will be calculated from raw data, and variances extracted or imputed and entered as fixed e ects (GIV) outcome, to provide summary weighted di erences and 95% confidence intervals (95%CI).
Dealing with missing data
We will contact investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
Any heterogeneity between the study results will be described and tested to see if it reaches statistical significance using a chisquared test. The 95%CI estimated using a random e ects model will be included whenever there are concerns about statistical heterogeneity. Heterogeneity is considered significant when the P value is < 0.10 (Higgins 2011).We will use the I statistic to measure heterogeneity among the trials in each analysis. If we identify substantial heterogeneity we will report it and explore possible causes by pre-specified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small study and publication biases.
Data synthesis
The results from studies that meet the inclusion criteria and reported any of the outcomes of interest will be included in the subsequent meta-analyses. The summary weighted risk ratio and 95%CI (fixed e ects model) will be calculated Review Manager (RevMan). For rate ratios of common events whereby one subject may have more than one event, GIV will be utilised. The rate ratios will be taken from the published papers and the standard errors calculated from CIs or P values published in the papers. For crossover studies, mean treatment di erences will be calculated from raw data, and variances extracted or imputed and entered as fixed e ects GIV outcome, to provide summary weighted di erences and 95%CI. Numbers needed to treat (NNT) will be calculated from the pooled OR and its 95%CI applied to a specified baseline risk using an online calculator (Cates 2008). The outcome indices will be assumed to be normally distributed continuous variables so the MD in outcomes could be estimated. If studies report outcomes using di erent measurement scales, the SMD will be estimated.
Summary of findings (SoF) table
We will create a 'Summary of findings' table using the following outcomes:
1. Number of participants who had one or more exacerbations over the study period, 2. Number of exacerbations per 52 weeks, 3. ICS dose at final visit The SoF table in the previous combined review (Petsky 2009 ) will be amended to reflect new data and restricted to the inclusion criteria. We will use the five GRADE considerations (study limitations, consistency of e ect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the metaanalyses for the prespecified outcomes. We will use methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro so ware (GRADEpro). We will justify all decisions to down-or up-grade the quality of studies using footnotes and we will make comments to aid reader's understanding of the review where necessary. 
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Subgroup analysis and investigation of heterogeneity
Subgroup analysis is planned for:
1. Basis for adjustment of ICS in the control group (guideline driven monitoring versus non-guideline driven) 2. Use of spirometry or peak flow as an adjunctive monitoring tool for adjustment of medications versus non-use of spirometry or peak flow 3. Baseline ICS dose at commencement of intervention (lowmedium [<800 mcg/day budesonide equivalent] versus high dose [800 mcg/day or more budesonide equivalent] 4. FeNO cut-o s for adjustment of medications (≤ 20 ppb versus > 20 ppb) 5. FeNO cut-o s, based on presence of atopy
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Sensitivity analysis excluding studies with a high risk of bias based on the 'Risk of bias' assessment. Studies that do not have adequate allocation concealment and sequence generation will be removed. 2. Variation in the inclusion criteria. Studies that included children not receiving ICS at recruitment will removed. 3. Di erences in the medications used in the intervention and comparison group. Studies that adjusted medications only for one arm will be removed. 4. Analysis used random e ects model 5. Analysis by "strategy received". Studies with hierarchy management protocols that only considered use of steroids for each step (i.e. without consideration for using montelukast and/ or LABA at any point) will be removed.
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